Geron reports USD 57.48 million revenue: Geron stock sits 39.30 percent below its high

Published on 10/20/2026 at 20:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Geron guides to USD 220 million to USD 240 million for 2026 RYTELO sales. Geron stock costs EUR 1.09 on October 20, 2026 at 8:33 p.m. CEST.

Revenue and reporting date

Geron reported USD 57.48 million in second-quarter 2026 revenue, up 11.70 percent year over year.
Business Quant recorded USD 51.45 million as the consensus comparison for the quarter.
Geron stock costs EUR 1.09 at Lang & Schwarz on October 20, 2026 at 8:33 p.m. CEST.
Geron is expected to report third-quarter results on November 4, 2026.

GERN, US3741631036, Illustration mit AI erstellt.

Geron Corporation reported USD 57.48 million in revenue for the second quarter ended June 30, 2026, up 11.70 percent from the same period a year earlier, while its Nasdaq price was USD 1.22 and 39.30 percent below the USD 2.01 52-week high on October 20, 2026. Benzinga reported that management expects RYTELO revenue to reach the mid to high end of its 2026 guidance range. Geron stock was trading at EUR 1.09 at Lang & Schwarz on October 20, 2026 at 8:33 p.m. CEST.

Revenue growth stays measurable

The quarter's revenue exceeded the USD 51.45 million consensus by USD 6.03 million, a 11.70 percent beat, according to Business Quant. The comparison matters because the commercial product is RYTELO, Geron's approved treatment for certain patients with lower-risk myelodysplastic syndromes.

Stock stays below its high

The Nasdaq quote reached USD 1.24 intraday and fell to USD 1.19, with volume of 2,072,076 shares on October 20, 2026. The USD 1.04 to USD 2.01 52-week range places the stock 17.31 percent above its low and 39.30 percent below its high. The market capitalization was USD 783.8 million on the same date.

Guidance and the next report

Geron expects 2026 RYTELO net product revenue of USD 220 million to USD 240 million and total operating expenses of USD 230 million to USD 240 million, according to Benzinga. The company also reported a USD 16.68 million net loss for the second quarter, while operating cash flow was negative USD 15.83 million for the period.

Stock Analysis lists November 4, 2026 as the next estimated earnings date. Its consensus section lists a USD 4.25 average target from five analysts, but that target is not used as the article's central market measure.

Comparison with peers

Geron's reported revenue growth and current loss profile leave the stock tied closely to commercial execution. The next report will test whether RYTELO revenue can continue moving above the USD 57.48 million second-quarter level.

Trading after the Xetra close

Geron operates in biotechnology and remains focused on commercializing RYTELO while advancing imetelstat studies in additional blood-cancer indications. The Nasdaq quote was USD 1.22 at 2:37 p.m. ET on October 20, 2026, while the euro quotation was EUR 1.09 at Lang & Schwarz at 8:33 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Geron stock.